Parkwood LLC Grows Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Parkwood LLC increased its position in AstraZeneca PLC (NASDAQ:AZN) by 62.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 118,199 shares of the company’s stock after buying an additional 45,514 shares during the period. Parkwood LLC’s holdings in AstraZeneca were worth $7,744,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Banque Transatlantique SA bought a new position in shares of AstraZeneca in the fourth quarter worth about $26,000. Albion Financial Group UT raised its stake in AstraZeneca by 68.9% during the 4th quarter. Albion Financial Group UT now owns 608 shares of the company’s stock valued at $40,000 after purchasing an additional 248 shares during the period. CoreCap Advisors LLC lifted its holdings in AstraZeneca by 31.8% in the 4th quarter. CoreCap Advisors LLC now owns 642 shares of the company’s stock worth $42,000 after purchasing an additional 155 shares in the last quarter. Golden State Wealth Management LLC bought a new position in AstraZeneca in the 4th quarter worth approximately $55,000. Finally, Crews Bank & Trust bought a new position in AstraZeneca in the 4th quarter worth approximately $55,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Down 1.8%

NASDAQ AZN opened at $67.72 on Wednesday. The stock has a 50 day moving average price of $70.96 and a 200-day moving average price of $69.60. AstraZeneca PLC has a one year low of $61.24 and a one year high of $87.68. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. The company has a market capitalization of $210.02 billion, a P/E ratio of 29.96, a P/E/G ratio of 1.42 and a beta of 0.40.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.14. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. The company had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. During the same quarter in the prior year, the firm earned $2.06 earnings per share. AstraZeneca’s revenue was up 7.2% on a year-over-year basis. As a group, equities analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on AZN shares. BNP Paribas initiated coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They set an “outperform” rating and a $75.00 price objective on the stock. Morgan Stanley began coverage on shares of AstraZeneca in a report on Wednesday, February 12th. They issued an “overweight” rating on the stock. Finally, UBS Group upgraded shares of AstraZeneca from a “neutral” rating to a “buy” rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $88.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.